3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2873
Carcinoma, Non-Small-Cell Lung
2426
Breast Neoplasms
2067
Colorectal Neoplasms
1245
Neoplasm Metastasis
1231
Prostatic Neoplasms
1080
Melanoma
974
Multiple Myeloma
963
Ovarian Neoplasms
904
Recurrence
852
Leukemia, Myeloid, Acute
810
Lung Neoplasms
757
Pancreatic Neoplasms
752
Lymphoma, Non-Hodgkin
727
Lymphoma
660
Stomach Neoplasms
623
Carcinoma, Hepatocellular
566
Carcinoma, Renal Cell
546
Squamous Cell Carcinoma of Head and Neck
529
Leukemia, Lymphocytic, Chronic, B-Cell
493
Lymphoma, Follicular
468
Head and Neck Neoplasms
451
Glioblastoma
435
Advanced Solid Tumors
432
Small Cell Lung Carcinoma
411
Triple Negative Breast Neoplasms
409
Lymphoma, Large B-Cell, Diffuse
398
Leukemia
394
Uterine Cervical Neoplasms
369
Advanced Solid Tumor
351
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA